Abeona Therapeutics Company Profile (NASDAQ:ABEO)

Analyst Ratings

Consensus Ratings for Abeona Therapeutics (NASDAQ:ABEO) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.67 (396.73% upside)

Analysts' Ratings History for Abeona Therapeutics (NASDAQ:ABEO)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Rodman & RenshawReiterated RatingBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015MLV & Co.Initiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/11/2015Roth CapitalInitiated CoverageBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2015HC WainwrightInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Abeona Therapeutics (NASDAQ:ABEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/16/2016        
5/16/2016Q1($0.13)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/20/2015Q215($0.10)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Abeona Therapeutics (NASDAQ:ABEO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Abeona Therapeutics (NASDAQ:ABEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Abeona Therapeutics (NASDAQ:ABEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/31/2015Mark J AhnDirectorBuy18,182$5.50$100,001.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Mark J AhnDirectorBuy25,000$4.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2014Steven H RouhandehDirectorBuy250,000$4.00$1,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Abeona Therapeutics (NASDAQ:ABEO)
DateHeadline
07/23/16 02:16 PMStock Up Nicely This Week: Abeona Therapeutics Inc. (NASDAQ:ABEO) - TGP
07/21/16 02:16 PMAbeona Therapeutics Inc. (ABEO) Current Analyst Ratings - Fiscal Standard
07/20/16 08:48 PMAnalysts' Updated EPS Estimates for July, 20th (ABEO, AGESY, AIQUY, ...
07/20/16 10:23 AMStock Moving Lower for the Month; Investor Update on Abeona Therapeutics Inc. (NASDAQ:ABEO) - Engelwood Daily
07/19/16 07:41 PMHeightened Volatility Spotted on Shares of: Abeona Therapeutics Inc. (NASDAQ:ABEO) - Engelwood Daily
07/19/16 07:41 PMStock Ticking Higher in Trading: Abeona Therapeutics Inc. (NASDAQ:ABEO) - TGP
07/19/16 07:41 PMTrading Action Review: Watching Unusual Volume on Abeona Therapeutics Inc. (NASDAQ:ABEO) - Engelwood Daily
07/19/16 08:28 AMAbeona Therapeutics Incorporated (NASDAQ:ABEO) Short Interest Decreased By 35.19% - Press Telegraph
07/18/16 01:15 PMINVESTOR ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Violations of Delaware Law by Certain Officers and Directors of Abeona Therapeutics Inc. - ABEO - [Accesswire] - NEW YORK, NY / ACCESSWIRE / July 18, 2016 / Levi & Korsinsky announces it has commenced an investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) concerning possible violations of Delaware law. To obtain ...
07/18/16 07:04 AMAbeona Therapeutics Inc. (ABEO) Broker Price Targets For The Coming Week - Fiscal Standard
07/16/16 02:16 PMAbeona Therapeutics Incorporated (NASDAQ:ABEO) Sellers Covered 4.03% of Their Shorts - Press Telegraph
07/13/16 02:18 PMInvestor News: Abeona Therapeutics Inc (NASDAQ:ABEO) under Investigation over possible Wrongdoing - GroundReport
07/13/16 10:21 AMInvestor News: Abeona Therapeutics Inc (NASDAQ:ABEO) under Investigation over possible Wrongdoing
07/10/16 07:03 AMAre Analysts Bullish Abeona Therapeutics Inc (NASDAQ:ABEO) After Last Week? - Press Telegraph
07/09/16 02:16 PMAbeona Therapeutics Incorporated (NASDAQ:ABEO) Shorted Shares Decreased By 4.03% - Press Telegraph
07/09/16 02:16 PMAbeona Therapeutics Incorporated (NASDAQ:ABEO) Shorted Shares Decreased By 4.03% - Press Telegraph
07/04/16 07:03 AMAbeona Therapeutics Incorporated (NASDAQ:ABEO) Shorted Shares Decreased By 4.03% - Engelwood Daily
07/03/16 07:03 AMCompany Stock Lower on the Week Abeona Therapeutics Inc. (NASDAQ:ABEO) - Engelwood Daily
06/30/16 07:44 PMAbeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - Marketwired (press release)
06/30/16 02:16 PMAbeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - Benzinga
06/30/16 10:08 AMAbeona Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
06/29/16 02:15 PMRecently Issued Stock Ratings For Abeona Therapeutics Inc. (ABEO) - Fiscal Standard
06/28/16 02:15 PMCheck on Share Volatility: Abeona Therapeutics Inc. (NASDAQ:ABEO) - Engelwood Daily
06/27/16 07:01 AMAbeona Therapeutics Inc. (ABEO) Updated Price Targets - FTSE News
06/25/16 10:05 AMAbeona Therapeutics Incorporated (NASDAQ:ABEO) Short Interest Decreased By 4.03% - Engelwood Daily
06/24/16 02:16 PMNew Broker Ratings For Abeona Therapeutics Inc. (ABEO) - FTSE News
06/24/16 02:16 PMShare Volatility Check for: Abeona Therapeutics Inc. (NASDAQ:ABEO) - Press Telegraph
06/22/16 02:16 PMAbeona Therapeutics Inc. (NasdaqCM:ABEO) Stock Momentum Hits Weakness - CML News
06/21/16 11:45 AMETF’s with exposure to Abeona Therapeutics, Inc. : June 21, 2016 -
06/20/16 08:48 AMThis Weeks Broker Views For Abeona Therapeutics Inc. (ABEO) - Fiscal Standard
06/07/16 04:26 PMETF’s with exposure to Abeona Therapeutics, Inc. : June 7, 2016 -
06/07/16 10:40 AMAbeona Therapeutics to Present at Jefferies 2016 Global Healthcare Conference - Marketwired (press release)
06/06/16 11:14 AMAbeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/04/16 10:43 AMAbeona Therapeutics to Present at 2016 BIO International Convention - Yahoo Finance UK
06/03/16 08:17 PMInvestigation for Investors in Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Announced
06/02/16 08:12 PMInvestigation for Investors in Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Announced - Digital Journal - Investigation for Investors in Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) AnnouncedDigital JournalDallas, TX based Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for rare disease. Abeona Therapeutics Inc reported that its annual Total Revenue rose from $.93 million in 2014 to $1.04 million in 2015 and that ...
06/02/16 10:53 AMAbeona Therapeutics to Present at 2016 BIO International Convention - Marketwired (press release) - Abeona Therapeutics to Present at 2016 BIO International ConventionMarketwired (press release)NEW YORK, NY AND CLEVELAND, OH--(Marketwired - June 02, 2016) - Abeona Therapeutics Inc. ( NASDAQ : ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and ...Analyst Review: Abeona Therapeutics Inc. (ABEO)Risers & Fallersall 2 news articles »
06/02/16 06:15 AMAbeona Therapeutics to Present at 2016 BIO International Convention - [at noodls] - NEW YORK, NY AND CLEVELAND, OH -- (Marketwired) -- 06/02/16 -- Abeona Therapeutics Inc.(NASDAQ: ABEO)a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products ...
05/31/16 07:55 AMAbeona Therapeutics (ABEO) – Analysts' Weekly Ratings Changes - Let Me Know About This - Abeona Therapeutics (ABEO) – Analysts' Weekly Ratings ChangesLet Me Know About ThisShares of Abeona Therapeutics Inc (NASDAQ:ABEO) traded up 1.24% during trading on Monday, hitting $3.26. The company had a trading volume of 141,167 shares. Abeona Therapeutics Inc has a 52-week low of $2.05 and a 52-week high of $8.66.
05/26/16 01:50 PMAbeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ... - Marketwired (press release) - Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ...Marketwired (press release)Abeona Therapeutics Inc. ( NASDAQ : ABEO), a clinical-stage biopharmaceutical company focused on delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced the FDA has allowed an ...Abeona Therapeutics Receives FDA Approval for Study of ABO-101 to Treat Sanfilippo Syndrome; Shares Flat Early ...Sonoran Weekly Reviewall 2 news articles »
05/24/16 01:55 PMRevenue Update on Abeona Therapeutics Inc(NASDAQ:ABEO) - Trade Calls - Revenue Update on Abeona Therapeutics Inc(NASDAQ:ABEO)Trade CallsAbeona Therapeutics Inc(NASDAQ:ABEO) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 17, 2016. Company reported revenue of $235.00K. Analysts estimated a revenue of $360.00K. Earnings ...Abeona Therapeutics to Present at UBS 2016 Global Healthcare ConferenceMarketwired (press release)Analyst Review: Abeona Therapeutics Inc. (ABEO)Risers & FallersAbeona Therapeutics Incorporated (NASDAQ:ABEO) Shorted Shares Increased By 0.83%Franklin IndependentThe Postall 5 news articles »
05/24/16 01:55 PMAbeona Therapeutics (ABEO) IND App for ABO-101 Phase 1/2 Allowed by U.S. FDA - StreetInsider.com - Abeona Therapeutics (ABEO) IND App for ABO-101 Phase 1/2 Allowed by U.S. FDAStreetInsider.comAbeona Therapeutics Inc. announced the FDA has allowed an Investigational New Drug (IND) Application for its Phase 1/2 Clinical Study with gene therapy candidate ABO-101 (AAV-NAGLU) for patients with Sanfilippo syndrome type B (MPS IIIB) to be ...and more »
05/24/16 06:16 AMAbeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB) - [at noodls] - NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 05/24/16 -- Abeona Therapeutics Inc. (NASDAQ: ABEO) ABO-101 is Abeona's second AAV gene therapy to commence clinical trials in a rare CNS disease The ...
05/24/16 06:05 AM7:05 am Abeona Therapeutics announces FDA has allowed IND application for phase 1/2 clinical study with gene therapy candidate ABO-101 for patients with Sanfilippo syndrome type B to be conducted at Nationwide Children's Hospital -
05/23/16 01:16 PMAbeona Therapeutics to Present at UBS 2016 Global Healthcare Conference - [at noodls] - NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 05/23/16 -- Abeona Therapeutics Inc.(NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based ...
05/20/16 01:18 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Violations of Delaware Law by Certain Officers and Directors of Abeona Therapeutics Inc. - [Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Abeona Therapeutics Inc. concerning possible violations of Delaware law. To obtain additional inf
05/17/16 03:40 PMABEONA THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/17/16 07:42 AMAbeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA) - [at noodls] - NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 05/17/16 -- Abeona Therapeutics Inc.(NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing products for severe and life-threatening ...
05/16/16 05:30 PMAbeona Therapeutics reports 1Q loss -
05/16/16 04:18 PMABEONA THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report -

Social

About Abeona Therapeutics

Abeona Therapeutics logoAbeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for rare diseases. The Company's programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the Company is also developing rare plasma protein therapies including SDF Alpha (alpha-1 protease inhibitor) for inherited COPD using its SDF (Salt Diafiltration) ethanol-free process.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABEO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.55
  • 50 Day Moving Average: $2.63
  • 200 Day Moving Average: $2.64
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $83.63M
  • Beta: 1.32
  • Current Year EPS Consensus Estimate: $-0.56 EPS
  • Next Year EPS Consensus Estimate: $-0.25 EPS
Additional Links:
Abeona Therapeutics (NASDAQ:ABEO) Chart for Tuesday, July, 26, 2016